- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Researchers uncover novel strategy to treat large B-cell lymphomas
Working independently of one another, two groups of researchers have uncovered a possible strategy involving a protease enzyme known as MALT1 to boost the effectiveness of treatment against diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin's lymphoma.
MALT1 is a protease enzyme; inside a cell it breaks down proteins. Prior research indicates that MALT1 also helps to "activate a signaling pathway that drives the growth of DLBCL cells called the nuclear factor-kappa B (NF-κB) pathway", according to the report in a recent NCI Cancer Bulletin.
When they inhibit MALT1's ability to do its job, researchers have found that they also shut down that signaling pathway, preventing growth and causing the cancerous B-cells to die.